Measuring childhood maltreatment: Psychometric properties of the Norwegian version of the Maltreatment and Abuse Chronology of Exposure (MACE) scale.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 30 11 2019
accepted: 12 02 2020
entrez: 28 2 2020
pubmed: 28 2 2020
medline: 19 5 2020
Statut: epublish

Résumé

Adverse childhood experiences in sensitive periods of the developing brain render the individual at a life-long risk for a broad spectrum of aberrant health outcomes. However, there is a lack of scales for the comprehensive assessment of adverse childhood experiences providing information of various types and the age of occurrence. Based on the complete, experimental version of the Maltreatment and abuse chronology of exposure (MACE-X) scale, the present study aimed to develop and psychometrically test a Norwegian version of MACE. The 75-item MACE-X was translated from German to Norwegian and administered as a self-report measure to 90 outpatients and 145 employees at a Division of specialized mental health care in South-Eastern Norway. The outpatients also completed the Childhood trauma questionnaire (CTQ) and the Symptom checklist 90 (SCL-90) to investigate convergent and predictive validity. To investigate test-retest reliability, outpatients completed MACE once more two weeks later. Rasch analysis and Anderson likelihood ratio tests on the combined outpatient and employee data resulted in a 55 item version of the Norwegian MACE. In the outpatient group, test-retest reliability of the MACE-55 was excellent for total scores (ICC ≥ 0.94) and good to excellent for 10 subscale scores (ICC ≥ 0.82). Convergent validity with the CTQ was moderate to high for both total scores (0.63 ≥ r ≥ 0.86) and subscale scores (0.56 ≥ r ≥ 0.82). As compared to CTQ total scores, a MACE total score that combined severity and duration of exposure was numerically more strongly associated with overall psychiatric symptoms and each of nine symptom domains on the SCL-90. The newly developed Norwegian MACE comprehensively assesses past exposure to adverse childhood experiences with high psychometric properties. This scale is a useful tool for research questions addressing sensitive periods for childhood adversities and associated health phenotypes.

Identifiants

pubmed: 32106231
doi: 10.1371/journal.pone.0229661
pii: PONE-D-19-31983
pmc: PMC7046287
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0229661

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Front Hum Neurosci. 2012 Mar 19;6:52
pubmed: 22457645
Biol Psychiatry. 2015 Feb 15;77(4):314-23
pubmed: 24993057
Qual Life Res. 2019 Apr;28(4):1029-1033
pubmed: 30547346
Biol Psychiatry. 2019 Apr 15;85(8):690-702
pubmed: 30528381
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
Psychopharmacol Bull. 1973 Jan;9(1):13-28
pubmed: 4682398
Scand J Psychol. 2013 Aug;54(4):286-91
pubmed: 23672336
BMC Psychiatry. 2016 Aug 19;16:295
pubmed: 27543114
Prev Chronic Dis. 2015 May 07;12:E70
pubmed: 25950577
Neuropsychopharmacology. 2016 Jan;41(1):3-23
pubmed: 26076834
Am J Psychiatry. 2012 Feb;169(2):141-51
pubmed: 22420036
Eur J Psychotraumatol. 2018 Mar 28;8(Suppl 7):1450594
pubmed: 29844885
PLoS Med. 2012;9(11):e1001349
pubmed: 23209385
J Child Psychol Psychiatry. 2016 Mar;57(3):241-66
pubmed: 26831814
Prev Chronic Dis. 2013 Dec 05;10:E205
pubmed: 24309093
J Am Acad Child Adolesc Psychiatry. 1997 Mar;36(3):340-8
pubmed: 9055514
Psychoneuroendocrinology. 2019 Oct;108:35-42
pubmed: 31226659
JAMA Psychiatry. 2019 Jun 26;:
pubmed: 31241756
Am J Psychiatry. 2020 Jan 1;177(1):20-36
pubmed: 31537091
Am J Prev Med. 1998 May;14(4):245-58
pubmed: 9635069
Arch Phys Med Rehabil. 1994 Feb;75(2):127-32
pubmed: 8311667
Compr Psychiatry. 2013 Feb;54(2):123-7
pubmed: 22901835
Schizophr Res. 2019 Mar;205:4-9
pubmed: 29141785
PLoS One. 2015 Feb 25;10(2):e0117423
pubmed: 25714856
Psychiatry Res. 2019 Feb;272:106-113
pubmed: 30580133

Auteurs

Roar Fosse (R)

Department of Mental health and addiction, Vestre Viken hospital trust, Asker, Norway.

Dag Vegard Skjelstad (DV)

Department of Mental health and addiction, Vestre Viken hospital trust, Asker, Norway.
Department of Psychology, University of Oslo, Oslo, Norway.

Inga Schalinski (I)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Medical Psychology, Berlin, Germany.

Dorothea Thekkumthala (D)

Department of Psychology, University of Konstanz, Konstanz, Germany.

Thomas Elbert (T)

Department of Psychology, University of Konstanz, Konstanz, Germany.

Chris Margaret Aanondsen (CM)

Institute of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Child and Adolescent Psychiatry, St. Olavs University hospital, Trondheim, Norway.

Hanne Klæboe Greger (HK)

Institute of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Child and Adolescent Psychiatry, St. Olavs University hospital, Trondheim, Norway.

Thomas Jozefiak (T)

Institute of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH